Compare Citius Pharmaceuticals Inc (CTXR) vs Dominion Energy Inc (D) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Dominion Energy Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Dominion Energy Inc trades at $67.94 (market cap $59.06B). The key difference: Dominion Energy Inc is far larger — about 3153.2× Citius Pharmaceuticals Inc's market cap, and Dominion Energy Inc pays a 3.98% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | D | |
|---|---|---|
Market Cap | $18.73M | $59.06B |
Sector | Health | Utilities |
52-Week High | $1.82 | $71.67 |
52-Week Low | $0.48 | $57.08 |
Enterprise Value | $14.95M | $113.18B |
Dividend Yield | — | 3.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Dominion Energy (D) trades at $67.39, up 0.88% today, with a bearish technical signal but strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.79, exceeding expectations, and maintains a stable dividend. Revenue growth is robust, rising to $16.51B in 2025, with a net income margin of 13.99%. Analyst consensus is mixed, with a $70.43 price target, but technical indicators show resistance near $68.
Outlook remains cautious due to high debt levels and bearish technicals, though fundamentals are solid with consistent profitability. Risks include regulatory pressures and capital expenditure demands. The stock offers income appeal with dividends, but near-term price action may face headwinds from technical selling pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Dominion Energy Inc
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →
